Application of cell sheets for therapy of refractory ulcers in ischemic hindlimbs

• Project/Area Number: 26462109
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular surgery
• Research Institution: Yamaguchi University
• Principal Investigator: MURAKAMI Masanori 山口大学, 医学部, 特別医学研究員 (30448295)
• Co-Investigator(Kenkyū-buntansha): 濱野 公一 山口大学, 医学(系)研究科(研究院), 教授 (60263787)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
• Keywords: ヒト細胞混合シート / ヒト末梢血単核球 / ヒト線維芽細胞 / VEGF / 細胞混合シート / 骨髄細胞シート / 虚血性足潰瘍 / 虚血性下肢潰瘍治療

Outline of Final Research Achievements

We performed functional analyses of mixed human cell sheets consisting of human peripheral blood mononuclear cells and human fibroblasts. The amount of vascular endothelial growth factor (VEGF) secreted from mixed human cell sheets was 2-fold higher than that from human fibroblasts. Furthermore, the amount of vascular endothelial growth factor (VEGF) secreted from mixed human cell sheets cultured under hypoxia (2% oxygen) was 2-fold higher than that from mixed human cell sheets cultured under normoxia (20% oxygen). These results revealed that mixture of human peripheral blood mononuclear cells with human fibroblasts and cell culture of mixed human cell sheets under hypoxia lead to enhanced secretion of VEGF.

Research Products

• [Presentation] 末梢血単核球と線維芽細胞からなるヒト細胞混合シートの難治性皮膚潰瘍治療に向けて (2017)
  • Author(s): 竹内由利子、上野耕司、溝口高弘、佐村 誠、原田剛佑、山下 修、西本 新、細山 徹、末廣晃太郎、森景則保、濱野公一
  • Organizer: 第47回日本心臓血管外科学会学術総会
  • Place of Presentation: グランドニッコー東京台場（東京都港区）
  • Year and Date: 2017-02-27